Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
The purpose of this study is to find out whether treatment with Serplulimab combined with Trastuzumab and Chemotherapy will improve the survival of gastric cancer patients with stage II-III after surgery.
Gastric Cancer
DRUG: Serplulimab|DRUG: Trastuzuma|DRUG: Chemotherapy
Disease-free survival, DFS, 3-year
Overall survival, OS, 3-year|Side effects, Complications such as Nausea, vomiting, myelosuppression and Liver or kidney function disorder, 12 months]
The purpose of this study is to find out whether treatment with Serplulimab combined with Trastuzumab and Chemotherapy will improve the survival of gastric cancer patients with stage II-III after surgery.